Retina Specialists

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration	Neovascular Age-related Macular Degeneration; nAMD	Recruiting	Phase 3	2026-09-29	NCT07614776
Extension Study for the Port Delivery System With Ranibizumab (Portal)	Neovascular Age-Related Macular Degeneration	Recruiting	Phase 3	2026-09-28	NCT03683251
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD	Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder	Recruiting	Phase 2	2026-09-10	NCT06659445
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56	wet macular degeneration	Active, not recruiting	Phase 3	2026-09-03	NCT06668064
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio	Geographic Atrophy Secondary to Age-related Macular Degeneration	Recruiting	Phase 2	2026-06-24	NCT07215390

Clinical trials